Delcath Systems (DCTH) Climbs +40% on Strong Q2 Results and Raised Guidance
Key Takeaways
- Delcath Systems (DCTH) climbed roughly 40% over the past 30 days, rising from about $12.22 to $17.14.
- The rally was driven by stronger-than-expected second-quarter 2026 results, reported before the open on August 6, 2026.
- HEPZATO KIT volume grew about 30% year over year, and the company activated its 31st active treatment center.
- Management raised full-year 2026 revenue guidance to a range of $104 million to $108 million.
- Delcath ended the quarter with $95.9 million in cash and investments and no debt.
Company Overview: Delcath Systems and Its Focus on Liver-Directed Cancer Therapy
Delcath Systems is an interventional oncology company focused on treating primary and metastatic cancers of the liver. Its lead product, HEPZATO KIT, combines the chemotherapy drug melphalan with a proprietary Hepatic Delivery System that isolates hepatic venous blood from systemic circulation, allowing high-dose chemotherapy to be delivered directly to the liver while limiting systemic exposure. In the United States, HEPZATO KIT is approved by the FDA as a liver-directed treatment for adult patients with metastatic uveal melanoma (mUM) who have unresectable hepatic metastases. In Europe, the device-only configuration is sold under the CHEMOSAT name.
As a commercial-stage company with a self-funding business model, Delcath stands out among small-cap oncology names for its cash-positive operations and debt-free balance sheet. Investors follow the stock closely because of its expanding treatment-center network, rising procedure volumes, and pipeline of additional liver-dominant cancer indications, including metastatic colorectal and breast cancer. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
DCTH Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, DCTH advanced from a closing price of approximately $12.22 to $17.14, a gain of about 40%. The move was not gradual: the stock jumped roughly 22% in a single session on August 6, 2026, immediately following its second-quarter earnings release, and then continued to trend higher through mid-August.
The broader three-month trend has been even stronger. From a level near $11 in late May 2026, the stock has risen more than 50%, reflecting sustained commercial momentum and improving investor confidence in the HEPZATO KIT rollout. The quarterly advance has been punctuated by higher trading volumes, particularly around earnings, indicating meaningful institutional and retail participation in the move. From what I see, the pattern suggests building conviction rather than a short-term spike.
What Drove DCTH Stock Price in the Last 30 Days
The primary catalyst was Delcath's second-quarter 2026 earnings report, released August 6, 2026. The company posted revenue of $29.1 million, up 20.6% from $24.2 million a year earlier, and HEPZATO KIT revenue of $27.1 million. Reported earnings per share of $0.07 significantly beat consensus estimates that had projected a loss. Management attributed the results to continued treatment-center expansion and a 30% year-over-year increase in HEPZATO KIT volume, which also rose 17% sequentially.
Equally important, Delcath raised its full-year 2026 revenue guidance to $104 million to $108 million, implying at least 28% growth in HEPZATO KIT volume over 2025. Gross margin improved to 90% for the quarter, and the company reported $5.7 million in operating cash flow. These results reinforced the view that Delcath's commercial strategy is scaling efficiently, and the stock repriced accordingly. One thing that stands out is how quickly the market digested the positive volume trends.
What Drove DCTH Stock Performance Over the Last Quarter
Beyond the immediate earnings beat, the quarterly advance reflects a broader commercial ramp. Delcath expanded its network to 31 active treatment centers and added several high-profile academic and NCI-designated institutions, including MD Anderson, UT Southwestern, Mayo Clinic Scottsdale, Oregon Health & Science University, and Columbia University's Herbert Irving Comprehensive Cancer Center. The company has also worked with centers to train backup REMS-certified teams, addressing a prior seasonal capacity constraint.
On the pipeline front, Delcath is advancing Phase II trials in metastatic colorectal cancer and breast cancer, and presented retrospective data at ESMO Breast Cancer in May 2026 showing hepatic partial responses in nine of 15 heavily pretreated patients. Combined with a debt-free balance sheet, positive operating cash flow, and an active share repurchase program, these developments have supported the stock's steady climb over the quarter. I’m watching this closely as the clinical data could expand the addressable market.
DCTH Stock Forecast Drivers: What Investors Should Watch Next
Looking ahead, investors will likely focus on the pace of new treatment-center activations, with management targeting roughly 37 active centers by year-end, and on whether procedure volume per site continues to grow. The ongoing 340B pricing program, which reduced the effective average selling price from about $185,000 to approximately $170,000 to $173,000 per kit, remains a factor to monitor against volume growth and gross margin guidance of 86% to 89%.
Clinical milestones also matter. Enrollment progress in the Phase II metastatic colorectal cancer trial and forthcoming data readouts could shape the long-term addressable market narrative. Broader macro conditions, small-cap healthcare sentiment, and the pace of the company's share repurchase program may also influence trading. As always, these factors carry risks, and outcomes are not guaranteed.
Exploring AI-Driven Trading Strategies
In my own analysis, I frequently review Tickeron’s platform for systematic approaches to stocks like this one. The Trending AI Robots page showcases a curated selection of AI-driven trading bots from a platform that operates hundreds of bots across thousands of tickers. Only the top-performing and most relevant bots are featured, making it a useful starting point for traders seeking data-driven strategies that match their risk tolerance. Explore the Trending AI Robots page to review the latest automated trading strategies and performance data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
DCTH's RSI Indicator recovers from overbought zone
The 10-day RSI Indicator for DCTH moved out of overbought territory on August 20, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 instances where the indicator moved out of the overbought zone. In 28 of the 34 cases the stock moved lower in the days that followed. This puts the odds of a move down at 82%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DCTH as a result. In 60 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for DCTH turned negative on August 26, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 32 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DCTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 60 cases where DCTH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
Following a +4.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where DCTH advanced for three days, in 208 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. DCTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 57 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.643) is normal, around the industry mean (10.748). DCTH's P/E Ratio (1621.000) is considerably higher than the industry average of (68.654). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.681). DCTH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.018). P/S Ratio (6.757) is also within normal values, averaging (39.536).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement